Avalo Therapeutics, Inc. · NASDAQ:AVTX

Avalo Therapeutics — Investor Presentation (December 2025)

21 slides from Avalo Therapeutics's investor presentation, Dec 2, 2025

  1. Slide 1: Corporate Overview December 2025

    ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and unc

  3. Slide 3: Advancing the Next-Generation of IL-1β Inhibition for Immune-Mediated Inflammatory Diseases

    Avalo Therapeutics: Advancing the Next-Generation of IL-1β Inhibition for Immune-Mediated Inflammatory Diseases 3 IL, interleukin; IND, investigational new drug application; mAB, monoclonal antibody; MOA, mechanism of action. 1. Vossen ARJV, et al. J Invest Dermatol. 2020;140(7):1463-1466.e2; 2. Kel

  4. Slide 4: Avalo Management Team

    Avalo Management Team 4 A proven track record of successful leadership, product development, and commercialization in pharma and biotech Colleen Matkowski SVP, Global Regulatory Affairs, Quality Assurance Dino C. Miano, PhD SVP, CMC, Technical Operations Chris Sullivan Chief Financial Officer Mittie

  5. Slide 5: AVTX-009: Designed to Target the Inflammatory Driver of HS

    AVTX-009: Designed to Target the Inflammatory Driver of Hidradenitis Suppurativa (HS) to Address Significant Unmet Need 5

  6. Slide 6: Chronic Inflammation in Hidradenitis Suppurativa Progresses to Tissue Destruction

    Chronic Inflammation in Hidradenitis Suppurativa Progresses to Tissue Destruction 6 Photos from Mendes-Bastos P, et al. Front Med (Lausanne). 2024;11:1403455; Ovadja ZN, et al. Brit J Dermatol. 2019;181:243-244; Cotter C, Walsh S. Skin Health and Disease. 2021;1(1):e7. CC-BY-4.0 License. 1. Diaz MJ,

  7. Slide 7: Persistent Unmet Need in HS Due to Limited Efficacy of Current Therapies

    Persistent Unmet Need in HS Due to Limited Efficacy of Current Anti- TNF and Anti-IL-17 Biologic Therapies 7 HS, hidradenitis suppurativa. aCurrent treatments include antibiotics, retinoids, steroids, Cosentyx®, Humira®. 1. Ingram JR, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1597-1605; 2. Kim

  8. Slide 8: IL-1β Plays a Central Role in the Pathophysiology of HS

    IL-1β Plays a Central Role in the Pathophysiology of HS 8 DAMP, damage-associated molecular pattern molecule; DC, dendritic cell; HS, hidradenitis suppurativa; IL, interleukin; R, receptor; PAMP, pathogen-associated molecular pattern molecule. Figure adapted from Agnese ER et al. Cureus. 15(11):e493

  9. Slide 9: Lutikizumab Data Highlights the Role for IL-1 in HS

    0% 10% 20% 30% 40% 50% Phase 2 Lutikizumab Data Highlights the Role for IL-1 in HS 9 *NS, not statistically significant ; All-ABX, patients who received any systemic antibiotic (new or increased dose) or who discontinued due to an adverse event or absence of efficacy were treated as nonresponders at

  10. Slide 10: AVTX-009 Is A Highly Potent, Specific Inhibitor of IL-1β

    AVTX-009 Is A Highly Potent, Specific Inhibitor of IL-1β • Clinical experience – 245 patients studied in phase 1 and phase 2 trials2,3-6 – Significant and rapid lowering of inflammatory biomarkers after a single dose of 0.6 mg – Well-tolerated and favorable safety profile at all doses up to 180 mg S

  11. Slide 11: AVTX-009 Potential Profile Advantages vs Lutikizumab

    Specificity IL-1 (α&β) IL-1β IL-1β binding affinity 44 KD (pM) <3 KD (pM) Subcutaneous bioavailability 46% 73% Half-life 10-14 days 19 days Dosing evaluated in HS study Q1W & Q2W4 Q2W & Q4W5 AVTX-009 Potential Profile Advantages: IL-1β Specificity, Higher Affinity, Bioavailability, and Longer Half-L

  12. Slide 12: Why Specificity Matters: IL-1β Predominant Isoform in HS

    0% 20% 40% 60% Why Specificity Matters: IL-1β is the Predominant IL-1 Isoform that Drives Chronic Inflammation in HS 12 HiSCR, hidradenitis suppurativa clinical response; HS, hidradenitis suppurativa; IL, interleukin; mAb, monoclonal antibody; QW, weekly, Q2W, every other week; wk, week. aFigure ada

  13. Slide 13: Why Affinity Matters in HS

    Why Affinity Matters in HS 13 mAbs, monoclonal antibodies. 1. Ryman JT & Meibohm B. CPT Pharmacometrics Syst Pharmacol. 2017.6:576-588; 2. Humira. Package insert. AbbVie Inc.; 2024; 3. Cosentyx. Package insert. Novartis Pharmaceuticals Corporation; 2024; 4. Witte-Händel E, et al. J Invest Dermatol.

  14. Slide 14: Phase 2 LOTUS Trial in Hidradenitis Suppurativa

    Phase 2 LOTUS Trial in Hidradenitis Suppurativa (AVTX-009-HS-201, NCT06603077) 14 ADA, antidrug antibody; AN, abscess and inflammatory nodule; CRP, C-reactive protein; DLQI, dermatology life quality index; EOS, end of study; EOT, end of treatment; HiSCR, Hidradenitis Suppurativa Clinical Response; H

  15. Slide 15: Diagnosed and Treated HS Population Projected to Grow into $10B+ Global Market by 2035

    Diagnosed and Treated HS Population is Projected to Grow Substantially into a $10B+ Global Market by 20351 15 HCP, healthcare provider; HS, hidradenitis suppurativa; U.S., United States. 1. HS Market Research 2024. Avalo Therapeutics Data on File; 2. Nguyen TV, et al. J Eur Acad Dermatol Venereol. 2

  16. Slide 16: Timelines: Looking Forward

    Timelines: Looking Forward 16 IND, investigational new drug application. aProjected; bPending readout from phase 2. MARCH 2024 JULY 2024 OCTOBER 2024 Q2 2026 2027 Merger with AlmataBio Active IND for AVTX-009 First patient enrolled in phase 2 LOTUS study LOTUS (phase 2) readouta Initiate pivotal pro

  17. Slide 17: Broad Potential for Indication Expansion

    Broad Potential for Indication Expansion: Clinical Rationale for IL-1 Targeting Therapies in Additional Disease States 17 CRP, C-reactive protein; CV, cardiovascular; DIRA, deficiency of interleukin receptor 1 antagonist; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; MI, myocardial

  18. Slide 18: Avalo Summary

    Avalo Summary (NASDAQ: AVTX) 18 IL, interleukin; mAB, monoclonal antibody. 1.Dinarello CA. Immunol Rev. 2018;281(1):8-27; 2. Bihorel S, et al. AAPS J. 2014;16(5):1009-1017; 3. Lacy SE, et al. mAbs. 2015;7(3):605-619; 2. Wang SX, et al. Osteoarthritis Cartilage. 2017;25(12):1952-1961; 4. Clinicaltria

  19. Slide 19: www.avalotx.com

    NASDAQ: AVTX www.avalotx.com 19

  20. Slide 20: Appendix

    avalo THERAPEUTIGS Appendix

  21. Slide 21: Key Financial Metrics

    Key Financial Metrics 21 1. Does not include 5.3M of stock options, restricted stock units and performance stock units outstanding resulting in a fully dilutive share count of 42.5M as of September 30, 2025, 2. Cash, cash equivalents and short- term investments, common shares outstanding, and prefer

Avalo Therapeutics — Investor Presentation (December 2025) on 6ix